ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
MBX Biosciences Inc

MBX Biosciences Inc (MBX)

20,27
0,78
(4,00%)
Fermé 20 Décembre 10:00PM
20,27
0,07
(0,35%)
Après les heures de négociation: 11:30PM

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

Dernier
20,27
Prix Achat
8,22
Prix Vente
22,50
Volume échangé
351 473
18,92 Fourchette du Jour 20,95
15,31 Plage de 52 semaines 26,19
Cap du marché
Clôture Veille
19,49
Ouverture
19,58
Dernière Transaction
14772
@
20.27
(formt)
Dernière heure de transaction
Volume financier
US$ 7 003 254
VWAP
19,9254
Volume moyen (3 m)
137 550
Actions en circulation
33 417 418
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-20,73
Bénéfice par action (BPA)
-0,97
Chiffre d'affairess
-
Bénéfice net
-32,56M

À propos de MBX Biosciences Inc

MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time... MBX Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endocrine and metabolic disorders. Our lead product candidate, MBX 2109, is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism, or HP. We designed MBX 2109 to treat the underlying pathophysiology of HP by providing a continuous, infusion-like exposure to parathyroid hormone, or PTH, with convenient once-weekly administration. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
Siège social
Wilmington, Delaware, USA
Fondé
-
MBX Biosciences Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker MBX. Le dernier cours de clôture d'MBX Biosciences était de US$19,49. Au cours de la dernière année, les actions de MBX Biosciences ont été négociées dans une fourchette de prix de US$ 15,31 à US$ 26,19.

MBX Biosciences compte actuellement 33 417 418 actions en circulation. La capitalisation boursière d'MBX Biosciences est de US$651,31 million. MBX Biosciences a un ratio cours/bénéfice (ratio PE) de -20.73.

MBX Dernières nouvelles

MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference

CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...

MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism

CARMEL, Ind., Dec. 02, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late...

MBX Biosciences to Participate in Upcoming November Investor Conferences

CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-2.28-10.11086474522.5522.8517.926328234819.58574804CS
44.0524.969173859416.2224.1915.6518581720.16919491CS
12-2.82-12.213079255123.0926.1915.3113755021.23994538CS
26-2.73-11.86956521742326.1915.3115929021.66692235CS
52-2.73-11.86956521742326.1915.3115929021.66692235CS
156-2.73-11.86956521742326.1915.3115929021.66692235CS
260-2.73-11.86956521742326.1915.3115929021.66692235CS

MBX - Frequently Asked Questions (FAQ)

What is the current MBX Biosciences share price?
The current share price of MBX Biosciences is US$ 20,27
How many MBX Biosciences shares are in issue?
MBX Biosciences has 33 417 418 shares in issue
What is the market cap of MBX Biosciences?
The market capitalisation of MBX Biosciences is USD 651,31M
What is the 1 year trading range for MBX Biosciences share price?
MBX Biosciences has traded in the range of US$ 15,31 to US$ 26,19 during the past year
What is the PE ratio of MBX Biosciences?
The price to earnings ratio of MBX Biosciences is -20,73
What is the reporting currency for MBX Biosciences?
MBX Biosciences reports financial results in USD
What is the latest annual profit for MBX Biosciences?
The latest annual profit of MBX Biosciences is USD -32,56M
What is the registered address of MBX Biosciences?
The registered address for MBX Biosciences is THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the MBX Biosciences website address?
The website address for MBX Biosciences is www.mbxbio.com.
Which industry sector does MBX Biosciences operate in?
MBX Biosciences operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PRFXPainReform Ltd
US$ 11,08
(410,60%)
95,4M
NVNINVNI Group Ltd
US$ 2,66
(315,63%)
20,64M
BPTHBio Path Holdings Inc
US$ 1,50
(124,22%)
113,42M
ZCARZoomcar Holdings Inc
US$ 2,5999
(96,96%)
18,03M
APCXAppTech Payments Corporation
US$ 0,6203
(62,81%)
196,08M
LITMSnow Lake Resources Ltd
US$ 0,3025
(-63,09%)
72,24M
BSFCBlue Star Foods Corporation
US$ 0,1478
(-48,14%)
7,45M
QUBTQuantum Computing Inc
US$ 15,1396
(-41,05%)
122,47M
QMCOQuantum Corporation
US$ 36,02
(-39,99%)
7,07M
AEMDAethlon Medical Inc
US$ 0,4232
(-35,94%)
9,52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,561
(53,78%)
725,18M
NVDANVIDIA Corporation
US$ 130,68
(1,37%)
209,74M
APCXAppTech Payments Corporation
US$ 0,6203
(62,81%)
196,08M
RGTIRigetti Computing Inc
US$ 7,465
(-30,17%)
176,12M
SOUNSoundHound AI Inc
US$ 18,855
(-9,55%)
139,39M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock